|
1
|
Wen PY and Reardon DA: Neuro-oncology in
2015: Progress in glioma diagnosis, classification and treatment.
Nat Rev Neurol. 12:69–70. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Patel M, Vogelbaum MA, Barnett GH, Jalali
R and Ahluwalia MS: Molecular targeted therapy in recurrent
glioblastoma: Current challenges and future directions. Expert Opin
Investig Drugs. 21:1247–1266. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cancer Genome Atlas Research Network:
Comprehensive genomic characterization defines human glioblastoma
genes and core pathways. Nature. 455:1061–1068. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Paulsson J, Lindh MB, Jarvius M, Puputti
M, Nistér M, Nupponen NN, Paulus W, Söderberg O, Dresemann G, von
Deimling A, et al: Prognostic but not predictive role of
platelet-derived growth factor receptors in patients with recurrent
glioblastoma. Int J Cancer. 128:1981–1988. 2011. View Article : Google Scholar
|
|
5
|
Guo D, Holmlund C, Henriksson R and Hedman
H: The LRIG gene family has three vertebrate paralogs widely
expressed in human and mouse tissues and a homolog in Ascidiacea.
Genomics. 84:157–165. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Simion C, Cedano-Prieto ME and Sweeney C:
The LRIG family: Enigmatic regulators of growth factor receptor
signaling. Endocr Relat Cancer. 21:R431–R443. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gur G, Rubin C, Katz M, Amit I, Citri A,
Nilsson J, Amariglio N, Henriksson R, Rechavi G, Hedman H, et al:
LRIG1 restricts growth factor signaling by enhancing receptor
ubiquitylation and degradation. EMBO J. 23:3270–3281. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shattuck DL, Miller JK, Laederich M, Funes
M, Petersen H, Carraway KL III and Sweeney C: LRIG1 is a novel
negative regulator of the Met receptor and opposes Met and Her2
synergy. Mol Cell Biol. 27:1934–1946. 2007. View Article : Google Scholar :
|
|
9
|
Ledda F, Bieraugel O, Fard SS, Vilar M and
Paratcha G: Lrig1 is an endogenous inhibitor of Ret receptor
tyrosine kinase activation, downstream signaling, and biological
responses to GDNF. J Neurosci. 28:39–49. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lindström AK, Ekman K, Stendahl U, Tot T,
Henriksson R, Hedman H and Hellberg D: LRIG1 and squamous
epithelial uterine cervical cancer: Correlation to prognosis, other
tumor markers, sex steroid hormones, and smoking. Int J Gynecol
Cancer. 18:312–317. 2008. View Article : Google Scholar
|
|
11
|
Hellberg D, Tot T and Stendahl U: Pitfalls
in immunohistochemical validation of tumor marker expression -
exemplified in invasive cancer of the uterine cervix. Gynecol
Oncol. 112:235–240. 2009. View Article : Google Scholar
|
|
12
|
Krig SR, Frietze S, Simion C, Miller JK,
Fry WH, Rafidi H, Kotelawala L, Qi L, Griffith OL, Gray JW, et al:
Lrig1 is an estrogen-regulated growth suppressor and correlates
with longer relapse-free survival in ERalpha-positive breast
cancer. Mol Cancer Res. 9:1406–1417. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang Y, Poulin EJ and Coffey RJ: LRIG1 is
a triple threat: ERBB negative regulator, intestinal stem cell
marker and tumour suppressor. Br J Cancer. 108:1765–1770. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sheu JJ, Lee CC, Hua CH, Li CI, Lai MT,
Lee SC, Cheng J, Chen CM, Chan C, Chao SC, et al: LRIG1 modulates
aggressiveness of head and neck cancers by regulating
EGFR-MAPK-SPHK1 signaling and extracellular matrix remodeling.
Oncogene. 33:1375–1384. 2014. View Article : Google Scholar
|
|
15
|
Ranhem C, Lillsunde Larsson G, Hedman H,
Lindquist D, Karlsson MG, Hellström AC, Östensson E, Sorbe B,
Hellman K and Andersson S: Expression of LRIG proteins as possible
prognostic factors in primary vaginal carcinoma. PLoS One.
12:e01838162017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rouam S, Moreau T and Broët P: Identifying
common prognostic factors in genomic cancer studies: A novel index
for censored outcomes. BMC Bioinformatics. 11:1502010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Guo D, Nilsson J, Haapasalo H, Raheem O,
Bergenheim T, Hedman H and Henriksson R: Perinuclear leucine-rich
repeats and immunoglobulin-like domain proteins (LRIG1-3) as
prognostic indicators in astrocytic tumors. Acta Neuropathol.
111:238–246. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Holmlund C, Haapasalo H, Yi W, Raheem O,
Brännström T, Bragge H, Henriksson R and Hedman H: Cytoplasmic
LRIG2 expression is associated with poor oligodendroglioma patient
survival. Neuropathology. 29:242–247. 2009. View Article : Google Scholar
|
|
19
|
Hedman H, Lindström AK, Tot T, Stendahl U,
Henriksson R and Hellberg D: LRIG2 in contrast to LRIG1 predicts
poor survival in early-stage squamous cell carcinoma of the uterine
cervix. Acta Oncol. 49:812–815. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Rondahl V, Holmlund C, Karlsson T, Wang B,
Faraz M, Henriksson R and Hedman H: Lrig2-deficient mice are
protected against PDGFB-induced glioma. PLoS One. 8:e736352013.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang B, Han L, Chen R, Cai M, Han F, Lei T
and Guo D: Downregulation of LRIG2 expression by RNA interference
inhibits glioblastoma cell (GL15) growth, causes cell cycle
redistribution, increases cell apoptosis and enhances cell adhesion
and invasion in vitro. Cancer Biol Ther. 8:1018–1023. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Xiao Q, Tan Y, Guo Y, Yang H, Mao F, Xie
R, Wang B, Lei T and Guo D: Soluble LRIG2 ectodomain is released
from glioblastoma cells and promotes the proliferation and inhibits
the apoptosis of glioblastoma cells in vitro and in vivo in a
similar manner to the full-length LRIG2. PLoS One. 9:e1114192014.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Mao F, Wang B, Xiao Q, Xi G, Sun W, Zhang
H, Ye F, Wan F, Guo D, Lei T, et al: A role for LRIG1 in the
regulation of malignant glioma aggressiveness. Int J Oncol.
42:1081–1087. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Xie R, Yang H, Xiao Q, Mao F, Zhang S, Ye
F, Wan F, Wang B, Lei T and Guo D: Downregulation of LRIG1
expression by RNA interference promotes the aggressive properties
of glioma cells via EGFR/Akt/c-Myc activation. Oncol Rep.
29:177–184. 2013. View Article : Google Scholar
|
|
25
|
Allen M, Bjerke M, Edlund H, Nelander S
and Westermark B: Origin of the U87MG glioma cell line: Good news
and bad news. Sci Transl Med. 8:354re32016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Holmlund C, Nilsson J, Guo D, Starefeldt
A, Golovleva I, Henriksson R and Hedman H: Characterization and
tissue-specific expression of human LRIG2. Gene. 332:35–43. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Andrae J, Gallini R and Betsholtz C: Role
of platelet-derived growth factors in physiology and medicine.
Genes Dev. 22:1276–1312. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Nazarenko I, Hede SM, He X, Hedrén A,
Thompson J, Lindström MS and Nistér M: PDGF and PDGF receptors in
glioma. Ups J Med Sci. 117:99–112. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Nakada M, Kita D, Watanabe T, Hayashi Y,
Teng L, Pyko IV and Hamada J: Aberrant signaling pathways in
glioma. Cancers (Basel). 3:3242–3278. 2011. View Article : Google Scholar
|
|
30
|
Paradowski M, Bilinska M and Bar J:
Characteristics of the expression of KAI1/CD82 and PDGFRβ and their
impact on glioma progression. Folia Neuropathol. 54:241–248. 2016.
View Article : Google Scholar
|
|
31
|
Holland EC, Celestino J, Dai C, Schaefer
L, Sawaya RE and Fuller GN: Combined activation of Ras and Akt in
neural progenitors induces glioblastoma formation in mice. Nat
Genet. 25:55–57. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
32
|
Brantley EC and Benveniste EN: Signal
transducer and activator of transcription-3: A molecular hub for
signaling pathways in gliomas. Mol Cancer Res. 6:675–684. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Reardon DA, Wen PY and Mellinghoff IK:
Targeted molecular therapies against epidermal growth factor
receptor: past experiences and challenges. Neuro Oncol. 16(Suppl
8): viii7–13. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Van Meir EG, Hadjipanayis CG, Norden AD,
Shu HK, Wen PY and Olson JJ: Exciting new advances in
neuro-oncology: The avenue to a cure for malignant glioma. CA
Cancer J Clin. 60:166–193. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Snuderl M, Fazlollahi L, Le LP, Nitta M,
Zhelyazkova BH, Davidson CJ, Akhavanfard S, Cahill DP, Aldape KD,
Betensky RA, et al: Mosaic amplification of multiple receptor
tyrosine kinase genes in glioblastoma. Cancer Cell. 20:810–817.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Laederich MB, Funes-Duran M, Yen L,
Ingalla E, Wu X, Carraway KL III and Sweeney C: The leucine-rich
repeat protein LRIG1 is a negative regulator of ErbB family
receptor tyrosine kinases. J Biol Chem. 279:47050–47056. 2004.
View Article : Google Scholar : PubMed/NCBI
|
